The study reports on a longlasting comparative RT‐qPCR/dPCR monitoring of BCR‐ABL1 transcript levels in 142 CML patients having a median duration of TKI treatment and DMR of 8.3 years and 5.9 years, respectively. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.